Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next.

By Jaimy Lee

The committee recommended the FDA reclassify four peptides, meaning compounding pharmacies can legally produce them. It will review three more peptides on Friday.

A group of independent advisers to the FDA is set to meet again Friday to vote whether to reclassify three more peptides, which would broaden their availability in the U.S.

A group of advisers to the Food and Drug Administration voted in favor of allowing pharmacies to compound peptides like BPC-157 and TB-500, which means the hot-button peptides may soon become more broadly available to Americans.

The FDA's leadership still has to weigh in. However, even if it agrees with the committee's recommendation and compounding begins, that does not mean that these products are FDA-approved. An FDA approval is a separate process that requires rigorous clinical testing and a regulatory review, a concern raised at Thursday's meeting.

The vote is part of a two-day meeting in which the advisers are voting whether to allow compounding pharmacies to make seven peptides that are used to promote improved health, in some cases by speeding up muscle recovery or improving sleep.

The products are popular with a group of unlikely allies, including the "looksmaxxing" and fitness communities, longevity experts, dermatologists and medical spas, and companies that operate compounding pharmacies like Noom and Hims & Hers Health, both of which made a name selling GLP-1 medications, which are also peptides. Hims' stock (HIMS) rallied 10% after the BPC-157 vote and closed 3.3% higher on Thursday.

They all stand to benefit from a peptide boom if the FDA decides to reclassify the seven peptides. The meeting on Thursday and Friday of independent advisers to the FDA includes votes on reclassifying each of the peptides under consideration.

"We can choose to build on the foundation that peptides like BPC-157n have given us and find a responsible way forward - one where patients stay under a clinician's care, where that care is monitored and studied, and where we steadily get better at how we use these therapies in the service of human health," Anant Vinjamoori, Hims' chief medical officer, said at Thursday's meeting. "Or we can decline to engage, cede the ground of the gray market, deny patient choice, and give up the chance to understand these compounds well enough to use them safely and to advance our understanding of human health along the way."

In recent years, peptides like BPC-157, KPV, TB-500, MOTS-C, emideltide, epitalon and Semax have been produced in a legal gray area.

Three years ago, the FDA placed restrictions on 14 peptides over safety risks, meaning they now fall somewhere between the unregulated world of supplements and the highly structured process of testing new drugs. People have continued to seek them out, often buying "for-research-use only" ingredients - sometimes from labs in China - mixing them, and then injecting them into their bodies. ("Everyone has a Chinese peptide dealer now" was a headline in the San Francisco Standard last year.)

Advocates of reclassification say putting regulatory guardrails in place will protect peptide users. A survey of 500 doctors recently conducted by Sermo found that 48% have had patients disclose that they used a non-FDA-approved peptide over the last year.

"The substance's supposed benefits are largely based on anecdotal evidence, and the interest in it appears to be driven by those who stand to benefit from increased demand," Nina Zeldes, a researcher in Public Citizen's Health Research Group, told the committee. "Although BPC 157 was discovered in the early 1990s, there is still no adequate data about its safety or effectiveness."

Opponents, however, are worried about the lack of research to back up the health claims and the safety risks that untested injections pose to patients. There have been several highly publicized incidents of people being hospitalized after taking a peptide, including two women attending the Revolution Against Aging and Death Festival in Las Vegas last year.

Alec Ginsberg, a fourth-generation pharmacist who owns C.O. Bigelow Apothecaries in New York, doesn't sell peptides in his store, which is stocked with a mix of vitamins, high-end beauty supplies and medications - all products he believes to be safe.

"I feel differently about peptides," Ginsberg said. "I would never wade into that because I won't sell anything that I think could lead to harm, and we don't know enough about them."

The FDA's own scientists have already recommended against reclassifying these peptides. They cite a lack of research; that nearly no other countries have approved use of these products; and concerns about how the peptides are made, including the degradation and concentration of active ingredients.

In their report, the staffers also noted that there have been few well-run studies assessing the safety and efficacy of peptides, which are essentially instructors, telling amino-acid chains how to fix or improve certain cells. Traditionally, before an FDA advisory committee meeting, the regulator's staff make their own recommendations. The individuals on the committee, which now includes several pro-peptide members, are then free to take different positions from that of the FDA scientists.

Here's what to know about the peptides under discussion this week:

Thursday's votes:

FDA advisers largely vote in favor of reclassifying BPC-157: The votes came in 8-6, with one abstention, in favor of reclassifying BPC-157, both in free-base and acetate form.

BPC-157 is well-known to peptide enthusiasts - and one of the few to have at least one study conducted in humans that appears to back up some of the claims for its benefits. It was discovered by researchers in Croatia in the 1990s and is primarily used as a treatment for interstitial cystitis, knee pain and ulcerative colitis. Some clinics call it the "wolverine compound" because of its healing properties, though New Zealand has recommended that BPC-157 is classified as a prescription drug.

Back in 2005, researchers conducted a randomized, double-blind, placebo-controlled study in 46 patients with ulcerative colitis. According to an abstract presented at a medical conference, there were improvements based on the Disease Activity Index, a common score for assessing the severity of ulcerative colitis. However, the FDA said the study lacked the information needed to support the safety and efficacy of BPC-157.

The advisors vote mostly 'yes' on KPV: Like BPC-157, the advisors voted along the same lines: eight in favor, six against, and one who abstained. KPV - or lysine (K), proline (P) and valine (V) - is mostly used for wound healing and skin health and to address other inflammatory conditions. One pharmacist requested that it only be allowed in topical form.

The FDA committee also voted to reclassify TB-500: TB-500 is another peptide primarily used for wound healing, though the FDA noted that it's marketed for at least 14 other health concerns, like hair loss, blood clots and dry-eye disorder. It was first synthesized from thymosin <BETA>4 in 2003 and has since been used to help horses and greyhounds improve racing performance.

It's often paired with BPC-157, in what users refer to as the "Wolverine stack."

Similar to the presentations for BPC-157 and KPV, advocates for this peptide acknowledged the lack of rigorous clinical data. But they also described the wound recoveries of specific patients who had undergone serious surgeries, cited their years of experience working with patients who took this peptide safety, and called for regulating products that patients will seek out anyway.

"Peptides need to be from a physician and a compounding pharmacist, and not, from what I've heard, a business card in the men's bathroom," said Elizabeth Yurth, co-founder of the Boulder Longevity Institute. "We have 10 years of supervised patient use."

Yet other physicans urged the FDA committee to consider the lack of clinical evidence. "What I'm looking at as a pharmacist, as a scientist, are clinical-based trials that are rigorous and demonstrate safety and efficacy," said John Herdig, chair of the board of the Collaborative for Evidence-Based Medicine, an organization that launched earlier this week.

Once again, the committee voted 8-6 in favor of reclassifying TB-500, with one absention. It also included a vote about free base and acetate form.

The FDA advisors say 'yes' to MOTS-C: People use this peptide, which is composed of 16 amino acids, to lose weight and better manage weight-related concerns like insulin resistance and metabolism. MOTS-C, which was discovered 11 years ago, is naturally occurring.

Advocates like James Lin, a geriatric-medicine specialist and president of the LECOM Institute for Successful Living in Erie, Pa., told the committee that MOTS-C helps address aging by improving key metrics like grip strength, metabolic function and bone loss, a sentiment echoed by several other speakers.

However, Adriane Fugh-Berman, a longtime critic of the drug industry and director of PharmedOut, an organization part of Georgetown University Medical Center that studies pharmaceutical marketing, took aim at the idea of reclassifying MOTS-C for compounding. She noted that one of every 20 approved therapies is a peptide and 170 peptides are currently in clinical trials.

"Peptides prepared to the highest standards are still untested experimental drugs," she said. "Allowing compounding, while not the same as drug approval, is nonetheless a nod to regulatory recognition."

This time, the FDA's advisors voted 7-5 in favor of putting MOTS-C on the compounding list. There were two abstentions. The vote was taken twice: once for free base and once for acetate.

Friday's votes:

(MORE TO FOLLOW) Dow Jones Newswires

07-23-26 1943ET